601089 福元医药
已收盘 12-31 15:00:00
资讯
新帖
简况
每周股票复盘：福元医药（601089）FY101临床进展符合预期
证券之星 · 2025-12-28
每周股票复盘：福元医药（601089）FY101临床进展符合预期
北京福元医药变更投资者联系电话及传真号码
中金财经 · 2025-12-27
北京福元医药变更投资者联系电话及传真号码
股市必读：福元医药（601089）12月25日披露最新机构调研信息
证券之星 · 2025-12-26
股市必读：福元医药（601089）12月25日披露最新机构调研信息
福元医药：景顺长城、华源证券等多家机构于12月24日调研我司
证券之星 · 2025-12-25
福元医药：景顺长城、华源证券等多家机构于12月24日调研我司
福元医药（601089）披露公司完成工商备案登记，12月18日股价下跌0.78%
证券之星 · 2025-12-18
福元医药（601089）披露公司完成工商备案登记，12月18日股价下跌0.78%
福元医药：华福证券、安信基金等多家机构于12月10日调研我司
证券之星 · 2025-12-11
福元医药：华福证券、安信基金等多家机构于12月10日调研我司
【机构调研记录】银华基金调研福元医药、航天南湖
证券之星 · 2025-12-08
【机构调研记录】银华基金调研福元医药、航天南湖
福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书
智通财经 · 2025-11-27
福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书
异动快报：福元医药（601089）11月26日9点58分触及涨停板
证券之星 · 2025-11-26
异动快报：福元医药（601089）11月26日9点58分触及涨停板
【机构调研记录】国联基金调研福元医药
证券之星 · 2025-11-24
【机构调研记录】国联基金调研福元医药
【机构调研记录】兴业基金调研福元医药
证券之星 · 2025-11-24
【机构调研记录】兴业基金调研福元医药
每周股票复盘：福元医药（601089）拟推股权激励计划
证券之星 · 2025-11-23
每周股票复盘：福元医药（601089）拟推股权激励计划
福元医药：中信证券、东吴基金等多家机构于11月19日调研我司
证券之星 · 2025-11-21
福元医药：中信证券、东吴基金等多家机构于11月19日调研我司
每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批
证券之星 · 2025-11-16
每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批
福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%
证券之星 · 2025-11-14
福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%
福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书
智通财经 · 2025-11-11
福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书
福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息
证券日报网 · 2025-11-05
福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息
每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%
证券之星 · 2025-11-02
每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%
福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%
证券之星 · 2025-10-30
福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%
图解福元医药三季报：第三季度单季净利润同比下降2.59%
证券之星 · 2025-10-29
图解福元医药三季报：第三季度单季净利润同比下降2.59%
加载更多
公司概况
公司名称：
北京福元医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-06-30
主营业务：
北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。
发行价格：
14.62
{"stockData":{"symbol":"601089","market":"SH","secType":"STK","nameCN":"福元医药","latestPrice":24,"timestamp":1767164401000,"preClose":24.32,"halted":0,"volume":2499311,"delay":0,"changeRate":-0.0132,"floatShares":480000000,"shares":480000000,"eps":0.9648,"marketStatus":"已收盘","change":-0.32,"latestTime":"12-31 15:00:00","open":24.41,"high":24.53,"low":23.95,"amount":60398200,"amplitude":0.0238,"askPrice":24.02,"askSize":4,"bidPrice":24,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.9648,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":24.32,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":26.75,"lowLimit":21.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":480000000,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":24.875622,"roe":"10.35%","epsLYR":1.04,"committee":0.27451,"marketValue":11520000000,"turnoverRate":0.0052,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-01-05。","floatMarketCap":11520000000},"requestUrl":"/m/hq/s/601089","defaultTab":"news","newsList":[{"id":"2594699242","title":"每周股票复盘：福元医药（601089）FY101临床进展符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2594699242","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594699242?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:47","pubTimestamp":1766864828,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，福元医药报收于24.29元，较上周的24.22元上涨0.29%。本周，福元医药12月25日盘中最高价报24.88元。本周关注点来自机构调研要点：FY101正按计划推进一期临床试验，结果符合公司预期。来自公司公告汇总：福元医药变更投资者联系电话为010-65020399，传真为010-65021289。漷县基地整体规划产能为100亿片，一期投产后将逐步释放产能，全部建成达产后可充分满足公司未来销售增长需求，为公司长期发展提供有力的产能保障。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2594211870","title":"北京福元医药变更投资者联系电话及传真号码","url":"https://stock-news.laohu8.com/highlight/detail?id=2594211870","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594211870?lang=zh_cn&edition=full","pubTime":"2025-12-27 09:19","pubTimestamp":1766798341,"startTime":"0","endTime":"0","summary":"中访网数据 北京福元医药股份有限公司于2025年12月27日发布公告，宣布变更投资者联系电话及传真号码。根据公告，自发布之日起，公司启用新的投资者联系电话010-65020399及传真号码010-65021289，以进一步提升投资者关系管理及服务质量。公司注册地址(北京市通州区通州工业开发区广源东街8号)、电子邮箱(ir@foyou.com.cn)及邮政编码(101113)等其他联系方式保持不变。此次变更旨在优化与投资者的沟通渠道，便于投资者更便捷地获取公司信息及进行咨询。公司证券代码为601089，证券简称为福元医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31896253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2594554062","title":"股市必读：福元医药（601089）12月25日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2594554062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594554062?lang=zh_cn&edition=full","pubTime":"2025-12-26 03:01","pubTimestamp":1766689277,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，福元医药报收于24.58元，上涨0.49%，换手率0.62%，成交量2.99万手，成交额7314.22万元。当日关注点来自交易信息汇总：12月25日主力资金净流出626.55万元，占总成交额8.57%。来自机构调研要点：募投项目“高精尖药品产业化建设项目（一期）”已结项，预计2026年全面达产，产能达60亿片。机构调研要点正按计划推进FY101的一期临床试验，当前结果符合公司预期，公司将依据信息披露要求及时公告项目进展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600000973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2594823923","title":"福元医药：景顺长城、华源证券等多家机构于12月24日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2594823923","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594823923?lang=zh_cn&edition=full","pubTime":"2025-12-25 19:01","pubTimestamp":1766660493,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月25日福元医药发布公告称景顺长城刘彦春 乔海英 陈婧琳 谢燕萍、华源证券刘闯 曹文泽、建信基金马牧青 郑丁源、工银瑞信基金刘倩于2025年12月24日调研我司。漷县基地整体规划产能为100亿片，一期投产后将逐步释放产能，全部建成达产后可充分满足公司未来销售增长需求，为公司长期发展提供有力的产能保障。福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500028844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239","161027"],"gpt_icon":0},{"id":"2592073159","title":"福元医药（601089）披露公司完成工商备案登记，12月18日股价下跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592073159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592073159?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:54","pubTimestamp":1766069660,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，福元医药报收于23.03元，较前一交易日下跌0.78%，最新总市值为110.54亿元。公司近日发布公告称，北京福元医药股份有限公司已于近日完成工商备案登记及《公司章程》备案手续。此次变更涉及取消监事会、增加董事会席位、修订《公司章程》以及公司董事信息变更。相关议案已于2025年10月28日和11月14日分别经第三届董事会第三次会议及2025年第二次临时股东会审议通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800039427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2590859410","title":"福元医药：华福证券、安信基金等多家机构于12月10日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590859410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590859410?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:03","pubTimestamp":1765447402,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月11日福元医药发布公告称华福证券陈铁林、安信基金池陈森、中信医药王凯旋、平安证券韩盟盟 倪亦道 曹艳凯、平安养老蔡晟 陶歆蔚、华源证券刘闯 孙洁玲、大成基金杨挺 陈泉龙 阳洪宇 徐雄晖 李煜 王晶晶于2025年12月10日调研我司。漷县基地整体规划产能为100亿片，一期投产后将逐步释放产能，全部建成达产后可充分满足公司未来销售增长需求，为公司长期发展提供有力的产能保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089","161027"],"gpt_icon":0},{"id":"2589801795","title":"【机构调研记录】银华基金调研福元医药、航天南湖","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801795?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:01","pubTimestamp":1765152098,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月5日披露的机构调研信息，银华基金近期对2家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司坚持“临床急需、仿创结合”策略，依托化学合成、口服固体制剂等平台，形成仿制药与创新药双轮驱动。仿制药聚焦心血管、神经、皮肤等领域，已有15个首仿产品，18个品种中标集采。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800000294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089","688552","BK0214"],"gpt_icon":0},{"id":"2586212006","title":"福元医药(601089.SH)：酮洛芬凝胶贴膏获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586212006","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586212006?lang=zh_cn&edition=full","pubTime":"2025-11-27 15:34","pubTimestamp":1764228897,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称“福元药业”)收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2586289340","title":"异动快报：福元医药（601089）11月26日9点58分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2586289340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586289340?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:01","pubTimestamp":1764122468,"startTime":"0","endTime":"0","summary":"证券之星11月26日盘中消息，9点58分福元医药触及涨停板。其所属行业化学制药目前上涨。领涨股为康芝药业。该股为创新药，减肥药，医药概念热股，当日创新药概念上涨2.2%，减肥药概念上涨2.07%，医药概念上涨1.95%。11月25日的资金流向数据方面，主力资金净流出529.35万元，占总成交额4.76%，游资资金净流出542.59万元，占总成交额4.88%，散户资金净流入1071.95万元，占总成交额9.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600007211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2585435435","title":"【机构调研记录】国联基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2585435435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585435435?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:01","pubTimestamp":1763942495,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，国联基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司截至2024年底研发人员达415人，FY101注射液正进行一期临床试验，预计明年启动二期。国联基金成立于2013年，截至目前，资产管理规模1486.77亿元，排名47/211；资产管理规模1227.98亿元，排名43/211；管理公募基金数187只，排名37/211；旗下公募基金经理28人，排名48/211。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585455435","title":"【机构调研记录】兴业基金调研福元医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2585455435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585455435?lang=zh_cn&edition=full","pubTime":"2025-11-24 08:01","pubTimestamp":1763942483,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月21日披露的机构调研信息，兴业基金近期对1家上市公司进行了调研，相关名单如下：1）福元医药 调研纪要：公司截至2024年底研发人员达415人，FY101注射液正进行一期临床试验，预计明年启动二期。兴业基金成立于2013年，截至目前，资产管理规模4171.34亿元，排名27/211；资产管理规模2452.86亿元，排名24/211；管理公募基金数207只，排名34/211；旗下公募基金经理28人，排名48/211。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400000213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585106602","title":"每周股票复盘：福元医药（601089）拟推股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2585106602","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585106602?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:35","pubTimestamp":1763843712,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，福元医药报收于22.01元，较上周的23.9元下跌7.91%。本周，福元医药11月17日盘中最高价报23.9元。福元医药当前最新总市值105.65亿元，在化学制药板块市值排名50/151，在两市A股市值排名1707/5167。FY101注射液正按计划开展一期临床试验，当前结果符合预期，预计将于明年启动二期临床试验。公司于2025年2月4日完成股份回购，累计回购12,000,000股，约占总股本2.50%，将用于股权激励计划，具体实施将结合战略规划适时推进。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2585112241","title":"福元医药：中信证券、东吴基金等多家机构于11月19日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2585112241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585112241?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:26","pubTimestamp":1763720789,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月21日福元医药发布公告称中信证券彭康 唐嘉奕 盛黎阳、东吴基金吴佳歆、平安资管林启姜、华商基金李海伟、方正证券李霁阳 茹帅 吕行之、中银基金王方舟、招商基金李稼存 周雨婷、鹏华基金王子建 蔡春根、国联基金刘柏川、信达澳亚杨柯、兴业基金解婕于2025年11月19日调研我司。福元医药主营业务：药品制剂及医疗器械的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100029412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","BK1521","LU1997245177.USD","LU1720050803.USD","601089","BK0239","LU2495084118.USD","600030","06030","LU0405327148.USD","BK0028","LU1997245094.SGD","BK0012","LU1655091616.SGD","LU2148510915.USD","LU1064131003.USD","LU1328615791.USD","LU1064130708.USD","LU1997244956.HKD","LU0405327494.USD","BK0276","BK0183","LU1794554557.SGD","LU2289578879.USD","BK0188","BK1564","BK0196","LU1255011170.USD","BK1516"],"gpt_icon":0},{"id":"2583989654","title":"每周股票复盘：福元医药（601089）依折麦布阿托伐他汀钙片获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2583989654","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583989654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:45","pubTimestamp":1763239511,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，福元医药报收于23.9元，较上周的21.77元上涨9.78%。本周，福元医药11月14日盘中最高价报24.67元。公司公告汇总北京福元医药股份有限公司近日收到国家药品监督管理局颁发的依折麦布阿托伐他汀钙片（Ⅰ）药品注册证书，批准该药品生产。会议应表决董事9名，实际表决9名，各项议案均获全票通过。子公司福元药业将投资32,320.79万元实施该项目，计划于2028年4月完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2583831507","title":"福元医药（601089）披露股东大会决议公告，11月14日股价上涨2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583831507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583831507?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:57","pubTimestamp":1763132240,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，福元医药报收于23.9元，较前一交易日上涨2.09%，最新总市值为114.72亿元。该股当日开盘23.3元，最高24.67元，最低23.18元，成交额达3.28亿元，换手率为2.84%。近日，福元医药发布2025年第二次临时股东大会决议公告。所有议案均获通过，无否决议案。会议召集召开程序合法，表决结果有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601089"],"gpt_icon":0},{"id":"2582755359","title":"福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582755359","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582755359?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:50","pubTimestamp":1762851013,"startTime":"0","endTime":"0","summary":"智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司收到了国家药品监督管理局(简称“国家药监局”)颁发的依折麦布阿托伐他汀钙片(Ⅰ)(规格：每片含依折麦布10mg与阿托伐他汀钙10mg(按C₃₃H₃₅FN₂O₅计))《药品注册证书》(证书编号：2025S03344)，批准该药品生产。依折麦布阿托伐他汀钙片(Ⅰ)由Organon研制，最早于2013年5月获FDA批准上市，2023年9月，经国家药品监督管理局批准，依折麦布阿托伐他汀钙片(Ⅰ)在中国上市，本品用于高胆固醇血症和纯合子型家族性高胆固醇血症(HoFH)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福元医药(601089.SH)：依折麦布阿托伐他汀钙片(Ⅰ)获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2581735757","title":"福元医药：公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581735757","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581735757?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:39","pubTimestamp":1762349940,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯福元医药11月5日在互动平台回答投资者提问时表示，为保障信息披露的公平原则，公司会在定期报告中依据相关法律法规披露股东人数以保证所有投资者平等获悉公司信息。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4141795.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4141795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2580912472","title":"每周股票复盘：福元医药（601089）Q3净利降2.59%，股东户数减少3.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580912472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580912472?lang=zh_cn&edition=full","pubTime":"2025-11-02 06:46","pubTimestamp":1762037170,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，福元医药报收于23.06元，较上周的22.04元上涨4.63%。本周，福元医药10月31日盘中最高价报23.38元。股本股东变化截至2025年9月30日，福元医药股东户数为22,691户，较6月30日减少796户，减幅3.39%。业绩披露要点2025年前三季度，福元医药实现营收25.21亿元，同比下降1.04%；归母净利润3.75亿元，同比下降6.39%；扣非净利润3.62亿元，同比下降4.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2579678119","title":"福元医药（601089）披露取消监事会、增加董事会席位及修订《公司章程》公告，10月30日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579678119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579678119?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:17","pubTimestamp":1761819431,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，福元医药报收于21.81元，较前一交易日下跌0.91%，最新总市值为104.69亿元。该股当日开盘22.1元，最高22.1元，最低21.68元，成交额达6993.81万元，换手率为0.67%。同日，福元医药发布公告，宣布拟取消监事会，其职权由董事会审计委员会行使，并废止《监事会议事规则》。公司董事会席位拟由8名增至9名，其中新增1名职工代表董事，独立董事保持3名不变。审计委员会将行使监事会的职权，股东会可授权董事会决定特定股票发行事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000036446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089","BK0239"],"gpt_icon":0},{"id":"2579903457","title":"图解福元医药三季报：第三季度单季净利润同比下降2.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579903457","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579903457?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:16","pubTimestamp":1761740182,"startTime":"0","endTime":"0","summary":"证券之星消息，福元医药2025年三季报显示，前三季度公司主营收入25.21亿元，同比下降1.04%；归母净利润3.75亿元，同比下降6.39%；扣非净利润3.62亿元，同比下降4.85%；其中2025年第三季度，公司单季度主营收入8.87亿元，同比下降0.55%；单季度归母净利润1.07亿元，同比下降2.59%；单季度扣非净利润1.04亿元，同比下降1.8%；负债率22.82%，投资收益1555.93万元，财务费用-444.92万元，毛利率65.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900041380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601089"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767454206052,"stockEarnings":[{"period":"1week","weight":-0.0188},{"period":"1month","weight":-0.048},{"period":"3month","weight":0.0738},{"period":"6month","weight":0.3953},{"period":"1year","weight":0.5455},{"period":"ytd","weight":0.5455}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京福元医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22691人(较上一季度减少3.39%)","perCapita":"21153股","listingDate":"2022-06-30","address":"北京市通州区通州工业开发区广源东街8号","registeredCapital":"48000万元","survey":" 北京福元医药股份有限公司的主营业务是药品制剂及医疗器械的研发、生产和销售。公司的主要产品是心血管系统类、慢性肾病类、皮肤病类、消化系统类、糖尿病类、精神神经系统类、妇科类、一次性使用吸氧管。公司已入选北京医药产业跨越发展工程G20企业，荣列中国药品研发综合实力百强榜。","listedPrice":14.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福元医药,601089,福元医药股票,福元医药股票老虎,福元医药股票老虎国际,福元医药行情,福元医药股票行情,福元医药股价,福元医药股市,福元医药股票价格,福元医药股票交易,福元医药股票购买,福元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福元医药(601089)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福元医药(601089)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}